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a b s t r a c t
A natural and biocompatible ﬁbrin microsphere is one of the most promising dual delivery
vehicle as compared to other traditionally designed delivery modalities. It represents sus-
tained delivery of encapsulated drug and is easily biodegradable in the blood circulation.
In the present study, we evaluated the systemic augmentation of the antifungal activity of
amphotericin B loaded in ﬁbrin microsphere (AMB-ﬁbrin microsphere) against cryptococ-
cosis in Swiss albino mice. Mice infected with Cryptococcus neoformans were treated with
0.5mg/kg AMB-ﬁbrin microsphere that was given alternately for 7 days. The antifungal
potential of AMB-ﬁbrin microsphere was assessed on the basis of reduction of cfu count
in the systemic circulation and various vital organs of infected mice. The formulation was
found to be highly effective in reducing intracellular pathogen from the experimental ani-
mals where ﬁbrin microsphere signiﬁcantly controlled the release of amphotericin B for
longer time duration. The AMB-ﬁbrin microsphere chemotherapy was signiﬁcantly more
effective than free amphotericin B in reducing the fungal burden and showed better sur-
vival efﬁcacy (p<0.05). The current study demonstrating the use of novel amphotericin Bloaded ﬁbrin microsphere not only imparts protection to the encapsulated amphotericin B
but also offers an effective strategy to decrease the drug associated toxicities.
ier Ed
delayed-type hypersensitivity in mice after vaccination with© 2016 Elsev
Introduction
Cryptococcus neoformans, a medically important opportunis-
tic fungal pathogen showing multi-organ involvement, has
been isolated from various natural sources like soil and rot-
ten vegetables.1 In human beings, C. neoformans is capable of
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causing pneumonia, meningitis and disseminated cryptococ-
cosis in the presence of impaired cell mediated immunity.2,3
Experimental studies have shown partial protection andvarious protein preparations.4–6 Prolonged survival and
reduced fungal burden responses have also been observed
after passive administration of anti-cryptococcal mAbs.7 In
e under the CC BY-NC-ND license (http://creativecommons.org/
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ecent years, Cryptococcus infection has shown tremendous
ncrease in its frequency of occurrence across the globe.8
espite the emerging new trend of this pathogen no vaccine
r immunotherapy has been found to avail complete protec-
ion against recurrence of C. neoformans challenge. Hence, the
evelopment of new chemotherapeutic strategieswill be help-
ul in conjunction with traditional drug delivery system to
ombat intracellular pathogens.
Amphotericin B (AMB) is the most effective antifungal
ntibiotic and is recommended as treatment of choice for dis-
eminated cryptococcal infections.8–10 A major factor limiting
he use of drug is poor accessibility to the intracellular
athogens. AMB is not used usually because of high toxicity
nd various side effects at high doses.9,11,12 The in-house pre-
esigned delivery system is a strategy to combat C. neoformans
ith improved delivery of the drug to the target site. Various
raditional drug delivery vehicles have the capability of intra-
ellular delivery of the antifungal or antibacterial agents and
ontrol its release over a prolonged period.4,13 Several workers
ave shown the encapsulation of AMB into the multilamillar
r unilamellar liposomes that release thedrug thereby steadily
educing its toxicity.14–16
In the recent past, plasma beads have been used for deliv-
ry of various biological components. The plasma beads are
omposed of recipient own blood plasma and are highly bio-
ompatible and biodegradable material.17 They can entrap
oth low and high molecular weight drugs and have an
bility to stay longer in blood circulation. In fact, plasma
eads could have an extra edge over other methods thus
ecoming a potential and safe drug-delivery vehicle. On
he other hand, poly-lactide co-glycolide (PLGA) microsphere
ased system has been designed to use constant delivery of
arious biological components, including drugs, antibiotics
nd proteins, etc.18,19 The in vitro designed PLGA micro-
pheres have revealed excellent biocompatibility. Concomi-
antly, due to non-toxicity, biodegradation, biocompatibility,
nd physiochemical properties, PLGA microspheres have a
road scope in being a potent chemotherapeutic delivery
ystem.20
aterials and methods
hemicals
mphotericinB, poly-lactide co-glycolide (PLGA) andpolyvinyl
lcohol (PVA) were purchased from Sigma–Aldrich, USA. All
ther chemicals used in this study were of highest purity.
xperimental animals
athogen free Swiss albino female mice with an average
eight of 18–22 g were used throughout the study. The ani-
als were fed rodent feed and ﬁltered water ad libitum.
he animals were housed in propylene cages on wood pow-
er bedding under standard atmospheric conditions (22±1 ◦C
emperature; 12h light/12 dark photoperiod and 50–60%
umidity). All experiments were performed according to the
uide for Experimental Animal Care Review Board, College of
harmacy, King Saud University.6;20(4):342–348 343
Experimental strain Cryptococcus neoformans
C. neoformans (ATCC 24067) strain was procured from Amer-
ican Type Culture Collection, USA. The strain was recovered
from glycerol stocks and maintained in yeast extract peptone
dextrose (YPD) media while shaking at 37 ◦C for 48h. The cell
suspension was centrifuged at 5000× g for 15min at 4 ◦C and
washed thrice with sterile normal saline. After quantifying
viable cell count the mice were infected intravenously with
C. neoformans (1×106 cfu/mouse).
Preparation of AMB suspension
AMB was diluted ﬁrstly in 5% glucose and subsequently in
phosphate buffered saline (PBS) and was given intraperi-
toneally (ip).
Preparation of plasma beads
For isolation of plasma, blood was collected through retro-
orbital puncture from healthy mice with a heparinized
capillary. Blood in heparin was centrifuged at 400× g at 4 ◦C
and plasma (supernatant) was isolated. An aliquot of plasma
(250L) was immediately used for preparation of plasma
beads whereas rest of the plasma was stored at −20 ◦C for
further use. Plasma beadswere prepared according to the pub-
lished protocol.21
Preparation of AMB encapsulated PLGA microsphere
Preparation of PLGA was based on water in-oil-in-water
(W/O/W) system. Microspheres were prepared by solvent
evaporation technique according to the published protocol.22
For the preparation of AMB encapsulated PLGA emulsion: 5mg
of AMB in 5% glucose was mixed with 190mg PLGA dissolved
in dichloromethane, 10% PVA was added to primary emul-
sion formed by sonication. After homogenization the resulting
O/W emulsion was stirred for 18h after which the formula-
tion of AMB-PLGA microsphere was centrifuged and washed.
The ﬁnal puriﬁed formulation was kept in dessication after
lyophilyzation at 4 ◦C.
Preparation of ﬁbrin microsphere
The ﬁbrin microsphere based dual delivery system was pre-
pared by encapsulating AMB in PLGAmicrosphere and further
entrapped in ﬁbrin beads according to the published protocol.4
Plasma (250L)wasmixedwith the suspension of AMB encap-
sulated PLGA microsphere in PBS. To the mixture, calcium
chloride (40mM) was also added. Aliquots (3L) of the mix-
ture were transferred as droplets over a paraﬁlm covered glass
slidewhichwere then incubated at 37 ◦C for 40min. The beads
after collecting from the paraﬁlm were washed with normal
saline and then with PBS.
Characterization of AMB-ﬁbrin microsphereThe particle size and surface morphology
Scanning electron microscopy (SEM; Zeiss EVO 40; Carl Zeiss
SMTAG, Oberkochen, Germany) of AMB-PLGA microsphere
i s . 20344 braz j infect d
was done to examine its surface morphology. A drop of
lyophilized preparation (20mM PBS, pH 7.4) was mounted on
a clear glass stub, air dried and coated with gold palladium
alloy. The particle size of ﬁbrin beads bearing AMB encapsu-
lated PLGAmicrosphereswas determined in the dry state. The
mean surface diameterwas calculated by themillimeter scale.
Determination of zeta potential
The lyophilized AMB-ﬁbrin microsphere was reconstituted in
phosphate buffer, pH 7.4 and added to the electrophoresis cell
of Zetasizer nanoZS instrument (Malvern Instrument Limited,
UK). The electrophoretic mobility and zeta potential values
were obtained using DTS software based on M3-PALS tech-
nology. The experiments were repeated three times and the
average zeta potential was calculated by taking the mean of
three values.
Determination of entrapment efﬁciency
The entrapment efﬁciency is the amount of drug entrapped in
the delivery vehicle with respect to the total amount of drug
used in the preparation of formulation. Published method
of Moynihan et al.23 was used to determine the entrapment
efﬁciency of AMB-PLGA microspheres and AMB-ﬁbrin micro-
spheres. A 10-mg samplewasmixedwith 1mL of 0.1N sodium
hydroxide solution and shaken at 37 ◦C to obtain a clear
solution. The supernatant of the solution was centrifuged
at 3000 rpm for 4min and then analyzed by NanoDrop 2000
(Thermo Scientiﬁc, USA). The AMB content in PLGA micro-
spheres and ﬁbrin microsphere was read at 405nm.
Determination of in vitro release proﬁle
The release kinetic assay indicates stability of AMB-ﬁbrin
microsphere under different pH conditions. The release of
AMBwas determined at three different pHmediums viz., pH 4,
pH 7, and pH 9. Measured aliquots of AMB-ﬁbrin microsphere
were taken in multiple vials to assess the release of AMB from
ﬁbrin microsphere. One mL of 20mM sterile PBS was added
to each vial and incubated at 25 ◦C. Release runs were con-
tinued for one week. At every alternate day, 100L aliquot
was taken from each vial. The aliquots were centrifuged at
9168× g for 10min and supernatants were spectroscopically
read at 405nm. The calculated amount of the released AMB in
different pH environment was plotted against time.
Determination of treatment dose of AMB
Healthy Swiss albino mice were divided into six groups of ﬁve
mice each. One group served as control and received 0.25mL
PBS, ip. The remaining groups were injected with different
amount of AMB. After 24h, the mortality rate of each group
was determined. The 0.5mg/kg b.w. dose of free drug resulted
in almost 50% survival of the treatedmice. Therefore, this dose
was used in present experiment. The selected dose is similar
to the already reported dose.18
Antifungal therapy using AMB-ﬁbrin microsphereAntifungal treatment was begun one day post-infection for a
period of seven days. Treatment was given once in the 1st, 3rd,
and 5th day post-infection. The pathogen infected mice were16;20(4):342–348
divided into ﬁve groups comprising of 10 animals each. The
mice of group I were used as untreated control and received
no treatment. Group II mice were injected with free AMB at a
single dose of 0.5mg/kg b.w. ip. Group III mice were injected ip
with 500L of AMB-plasma beads. In Group IV, the mice were
treated with AMB-PLGA microsphere at a dose of 0.5mg/kg
b.w. in 500L; ip. Group V mice were injected ip with 500L of
AMB-ﬁbrin microsphere.
Determination of fungal burden in various vital organs
The efﬁcacy of AMB-ﬁbrin microsphere against severity of C.
neoformans was conﬁrmed by assessing the cfu count in vari-
ous vital organs, namely lung, brain and blood. The mice from
experimental groups were euthanized in the 7th, 14th and
21st day post-infection and organs were taken out aseptically.
The organs were homogenized separately in 5mL PBS and an
aliquot of the homogenatewas plated on YPD agar plates after
appropriate dilutions. The number of colonies in each group
were noted after 48h of incubation at 37 ◦C. The fungal load in
each organ was calculated by multiplying with the respective
dilution factor.
Survival studies
The efﬁcacy of the formulation was further conﬁrmed by
monitoring the survival of remaining mice from experimen-
tal groups. For survival studies, mortality of the mice was
observed twice each day during 60 days of observation.
Statistical analysis
The data were analyzed by one-way analysis of variance
(ANOVA) following Student’s t-test. p values of <0.05 were con-
sidered statistically signiﬁcant. All analyses were performed
with SPSS v20.0 software.
Results
Characterization of AMB-ﬁbrin microsphere
Fig. 1a shows the ﬁbrin microsphere beads formed with 3L
calcium-enriched plasma. The beads were spherical in shape
with diameter between 1.0 and 1.5mm. Fig. 1b shows the
size and surface morphology of AMB-PLGA microspheres as
revealed by SEM. PLGA microspheres were spherical in struc-
ture and their size varied in the range of 300–800nm (Fig. 1b).
The size of the AMB-PLGAmicrosphere was further conﬁrmed
with the particle size analyser and it was in good agreement
with their diameter (Fig. 1c).
Entrapment efﬁciency, release kinetics and zeta potential
of AMB-ﬁbrin microsphereThe entrapment efﬁciency of AMB-PLGA microsphere and
AMB-ﬁbrin microsphere was obtained to be 65.6±2.5 and
78.31±4.7, respectively. The zeta-potential stability of AMB-
ﬁbrin microsphere was found to be −35±2.0mV.
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Fig. 1 – Image depicting AMB-ﬁbrin microsphere. (A) A picture of ﬁbrin beads bearing AMB loaded PLGA microspheres
(AMB-ﬁbrin microsphere), (B) scanning electron micrograph of AMB loaded PLGA microspheres, AMB loaded PLGA
microspheres visualized by the nanophox particle size analyzer.
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Fig. 2 – Percent release of AMB from ﬁbrin microsphere.The AMB-ﬁbrin microsphere was found to withstand both
ormal and alkaline conditions for a period of 48h (Fig. 2).
or ﬁrst two days, the formulation at pH 7 showed sustained
elease pattern, where only ∼10 to 30% of AMB was released
rom the total amount loaded in the ﬁbrin microsphere. The
est of the 89% of AMB was released from formulation in one
eek. However, the whole AMB leaked out in the 4th and 5th
ays at pH 4 and 9, respectively.
herapeutic potential of AMB-ﬁbrin microsphere against
ryptococcosis
he effects of AMB-ﬁbrin microsphere were investigated
gainst C. neoformans in murine model. In the ﬁrst set of
xperiments, the fungal burden in tissues was taken into con-
ideration.All themice of treatment groupswere infectedwith
×106 cfu/mouse ofC. neoformans. The antifungal therapywas
tarted one day post-infection on alternate days. The mice
ere euthanized in the 7th day of therapy for determining
arly tissue burden and in the 14th and 21st days for deter-
ining late tissue burden. The effect of therapy on reduction
n fungal burden in blood, brain, and lung is shown in Figs. 3–5,
Fibrin microsphere containing entrapped AMB was
incubated in different pH at 25 ◦C and release kinetics of the
drug was determined spectrophotometrically. Each value
represents mean±SD of three determinations.
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Fig. 3 – Effect of AMB-ﬁbrin microsphere therapy on fungal
burden in blood of mice infected with C. neoformans.
Antifungal efﬁcacy was recorded as reduction in fungal
load at days 7, 14, and 21 post-infection. The data represent
the mean cfu/organ of three different experiments±SD.
Fig. 4 – Effect of AMB-ﬁbrin microsphere therapy on fungal
burden in brain of mice infected with C. neoformans.
Antifungal efﬁcacy was recorded as reduction in fungal
load at days 7, 14, and 21 post-infection. The data represent
Fig. 5 – Effect of AMB-ﬁbrin microsphere therapy on fungal
burden in lung of mice infected with C. neoformans.
Antifungal efﬁcacy was recorded as reduction in fungal
load at days 7, 14, and 21 post-infection. The data represent
in prolonging survival than AMB-PLGA microsphere, AMB-the mean cfu/organ of three different experiments±SD.
respectively. In the blood, AMB-ﬁbrin microsphere therapy
was more effective than free AMB (Fig. 3). The AMB-ﬁbrin
microsphere therapy showed signiﬁcant (p<0.05) reduction in
the fungal load in blood from 4.12±0.019 mean cfu on day 7
to 1.68±0.018 mean cfu on day 21 as compared to the fun-
gal burden in untreated control (4.91±0.001 mean cfu on day
7). Free AMB was able to reduce fungal burden till day 7 onlythe mean cfu/organ of three different experiments±SD.
(4.00±0.026 mean cfu). In contrast, AMB-PLGA microsphere
was also able to reduce the total load of C. neoformans present
in blood from 3.18±0.019 mean cfu on day 7 to 2.68±0.018
mean cfu on day 21.
AMB-ﬁbrin microsphere was superior at reducing fungal
burden in brain (Fig. 4). The mean cfu values 4.01±0.021 (day
7), 3.23±0.021 (day 14), and 2.19±0.023 (day 21) demonstrates
a signiﬁcant (p<0.05) reduction in fungal burden in brain
upon treatment with the formulation as compared to mean
cfu value of 4.91±0.005 (day 7) and 6.34±0.003 (day 14) of
untreated controls. Free AMB was unable to invoke signiﬁcant
antifungal response.
In the lung, the AMB-ﬁbrin microsphere therapy was also
found more effective than free AMB (Fig. 5). For C. neoformans,
the ﬁbrin microsphere as well as AMB-PLGA microsphere
with the exception of free AMB and AMB-ﬁbrin beads were
signiﬁcantly effective at reducing fungal burden relative to
untreated controls (p<0.05). TheAMB-ﬁbrinmicrosphere ther-
apy was signiﬁcantly more effective (mean cfu 4.10±0.003,
day7; 3.01±0.014, day 14; 1.65±0.015, day 21) than untreated
controls (mean cfu 4.89±0.005, day 7; 6.87±0.007, day 14) at
reducing fungal burden in the lung.
Survival of treated mice
For survival studies, the mice were observed throughout 60
days, and deaths were recorded twice daily. The survival
curves of all treated groups are presented in Fig. 6. For C. neo-
formans infection, AMB-ﬁbrin microsphere was more effectiveﬁbrin beads or free AMB. However, the survival of mice treated
with the formulation andAMB-PLGAmicrospherewere signif-
icantly different relative to the untreated controls (p<0.05).
braz j infect d i s . 201
Fig. 6 – Prophylactic potential of AMB-ﬁbrin microsphere in
terms of survival of mice that were infected with C.
neoformans. The mice were monitored for survival till day
60 post-infection. Data represents mean±SD of three
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dual delivery system can become a more promising approachifferent experiments.
MB-ﬁbrin microsphere based dual therapy increased the
urvival time of treated mice where almost 80% of the ani-
als survived day 60 post-infection. Treatment with free AMB
esulted in survival of 40%of the animals till day 60. AMB-PLGA
icrosphere and AMB-ﬁbrin beads therapy did also improved
he survival rate by 60% and 50%, respectively, as compared to
he untreated controls (p<0.05) at day 60 post-infection. In the
ntreated control group, infection with C. neoformans resulted
n 100% mortality by day 20 post-infection.
iscussion
n spite of the fact that the drug delivery system has been
roven to be the most successful medical intervention ever
eveloped, there has been tremendous scope for further
mprovement to control infectious diseases in human as well
s in other mammalian species. The concept of using poly-
ers and blood plasma in a dual delivery system has been
onceived because they release the entrapped drug in a sus-
ained manner in the surrounding milieu. After efﬁciently
eleasing the drug, these biocompatible and biodegradable
olymers break down to lactic acid and glycolic acid that
re eventually excreted through the normal process. Plasma,
he other component of the system, being part of blood is
asily absorbed in the host body upon delivery. So, plasma
eads based microspheres will act as a slow release vehicle
or delivering the encapsulated drug safely to treat intracel-
ular pathogens. In the present study, the potential of these
wo components as a vehicle in dual delivery system is docu-
ented for therapeutic transport of the antifungal drug AMB
gainst C. neoformans infection in mice.
Fibrin microsphere as the dual delivery system has an
xceptional beneﬁt of minimizing the risks of infection and
llergic reactions. This is because they are prepared from
hole plasma and no extrinsic component is used. Unlike
ther delivery vehicles, plasma beads are made uniformly6;20(4):342–348 347
with equal dimension and large number of beads can be pre-
pared in a short time. Water insoluble and large molecular
weight substances are released from plasma beads by diffu-
sion and subsequently by degradation of ﬁbrin matrix.24,25
Moreover, antifungal drugs possess the ability to bind strongly
to the plasma beads26 where entrapped drug is released more
slowly from larger beads.18 Likewise, PLGA microsphere is
also a well designed drug delivery vehicle that show sus-
tained release of encapsulated drug. In accordance with the
above mentioned characteristics, the ﬁbrin microsphere sys-
tem showed strong entrapment efﬁciency of about 78% and
released AMB slowly in a sustained manner at all tested pH
medium (Fig. 2). These parameters support the characteristic
potential of AMB-ﬁbrin microsphere as a novel dual delivery
system.
After determining the fusogenic potential of AMB
entrapped in ﬁbrin microsphere, its antifungal efﬁcacy
was tested in experimental murine cryptococcosis. Anti-
fungal efﬁcacy is directly linked to the time of beginning of
therapy. It is a general statement that delay in treatment
reduces antifungal efﬁcacy.27 Considering this, chemotherapy
was started at day 1 post-infection of mice with C. neoformans
(1×106 cfu/mouse). The dose of AMB used had already been
shown to be non-toxic inmice as it did not increase the serum
creatinine levels.28
The effects of antifungal therapy were established in terms
of fungal burden and survival of treated mice. For determin-
ing fungal burden, the decrease in cfu count of C. neoformans
was recorded in the systemic circulation, and lung and brain,
the two most affected organs. Post chemotherapy, free AMB,
AMB-PLGA and AMB-plasma beads were able to reduce the
fungal burden but was not comparable with the AMB-ﬁbrin
microsphere treated animals. AMB-ﬁbrinmicrosphere treated
animals showed a more pronounced regression of C. neofor-
mans infection as compared to the other delivery systems
(Figs. 3–5). The efﬁcacy of chemotherapy by AMB-ﬁbrin micro-
sphere lasted till 21 days. After that no effect was observed
on residual fungal burden. The free AMB therapy lasted for
only seven days after which no change in fungal burden was
recorded at days 14 and 21 (Figs. 3–5). This could be due to
clearance of AMB from the infected organs at these times.
The effect of AMB is in accordance with already published
reports.29,30 Most importantly, the effect of therapy with AMB
entrapped in ﬁbrin microsphere persisted for longer time
period than other tested forms. Similarly, the survival rate
(Fig. 6) was remarkably improved in AMB-ﬁbrin microsphere
treated mice as compared to those treated with other formu-
lations. Overall, the effective suppression of the virulence of
C. neoformans infection for a longer period demonstrates the
superiority of the ﬁbrin microsphere based delivery system.
Consequently, in the present study, the use of plasma
beads-PLGA based ﬁbrin microsphere as a delivery vehicle for
AMBhasbeenestablished toplay apivotal role in the clearance
ofC. neoformans infection inmice. TheAMB-ﬁbrinmicrosphere
based therapy showed negligible fungal burden in the ana-
lyzed tissues after treatment. Delivery of AMB incorporated inthan the mono delivery for the treatment of C. neoformans
infection. This form of chemotherapy could have an extra
advantage over the other traditional drug delivery modalities
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currently used. Themost eye-catching feature is that the ﬁbrin
microsphere can be prepared from a host own blood plasma
and involvesminimumrisk in thehost upon subsequent expo-
sure that would be required of the concerned person hence
further.
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